12:00 AM
 | 
Apr 06, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tykerb lapatinib regulatory update

GlaxoSmithKline submitted an sNDA to FDA for Tykerb lapatinib as first-line treatment of hormone-sensitive, advanced or metastatic breast cancer in combination with anti-hormonal therapy. Additionally, the company...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >